title: Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis.
abstract: Methotrexate (MTX) is currently under study for use in juvenile rheumatoid arthritis. One complication of MTX is hepatotoxicity. Although liver function tests may be abnormal with its use, in this setting they do not correlate well with the development of hepatic fibrosis. Periodic liver biopsy is required to monitor for the hepatotoxic changes secondary to MTX. We describe and discuss the case of a 17-year-old woman who developed evidence of hepatic fibrosis after 3 years of MTX therapy.
authors.affiliation: Department of Pediatrics, University of Michigan Hospitals, Ann Arbor.
authors.forename: D
authors.initials: D
authors.lastname: Keim
authors.forename: C
authors.initials: C
authors.lastname: Ragsdale
authors.forename: K
authors.initials: K
authors.lastname: Heidelberger
authors.forename: D
authors.initials: D
authors.lastname: Sullivan
mesh_terms: D000293:Adolescent; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001706:Biopsy; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000139:chemically induced*; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D008727:Methotrexate